NEW YORK (GenomeWeb News) – ACS Biomarker reported on Friday it has closed on a financing round and appointed a new CEO.
The amount of the funding was not disclosed. In a statement, the company, based in Maastricht, Netherlands, said it will be used to further develop its product pipeline and discover novel biomarkers "that improve diagnosis, prognosis, and management of cardiac diseases."
Funding came from Life Sciences Fund Amsterdam and Limburg Ventures, ACS said.
ACS Biomarker, spun out of Maastricht University Medical Centre in 2007, recently established an office and research facility in Amsterdam. Its R&D is focused on miRNA- and protein-based cardiovascular biomarkers.
Its first protein biomarker, galectin-3, was licensed to BG Medicine, whose test for heart failure based on the biomarker was cleared by the US Food and Drug Administration in November.
The company also said it has appointed a new CEO, Heico Breek, who said in a statement that his main objective will be on the expansion and commercialization of ACS Biomarker's portfolio.